Sitemap > Breaking Research > Cardiovascular Disorders
Displaying 651 - 700 of 4862 results
- FTY720 inhibits tumor growth and angiogenesis.
- A novel immunomodulator KRP-203 combined with cyclosporine prolonged graft survival and abrogated transplant vasculopathy in rat heart allografts.
- Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial.
- The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry.
- Overexpression of sorcin enhances cardiac contractility in vivo and in vitro.
- Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension.
- Change in body mass index and its impact on blood pressure: a prospective population study.
- Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity.
- The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure.
- Inhibition of ribonucleotide reductase reduces neointimal formation following balloon injury.
- Endothelial-like cells expanded from CD34+ blood cells improve left ventricular function after experimental myocardial infarction.
- Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.
- Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption.
- Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis.
- Gene transfer of inhibitor kappaB in human lung cancer cell line NCI-H460 inhibits tumorigenesis and angiogenesis in vivo.
- Roxithromycin inhibits angiogenesis of human hepatoma cells in vivo by suppressing VEGF production.
- Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist.
- A comparison of tacrolimus and cyclosporine in liver transplantation: effects on renal function and cardiovascular risk status.
- Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
- Lipid-lowering therapy in patients with peripheral arterial disease: are guidelines being met?
- Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction.
- A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol.
- The efficacy of a 'master switch gene' HIF-1alpha in a porcine model of chronic myocardial ischaemia.
- Antithrombotic properties of the thromboxane A2/prostaglandin H2 receptor antagonist S18886 on prevention of platelet-dependent cyclic flow reductions in dogs.
- Simvastatin reduced ischemic brain injury and perfusion deficits in an embolic model of stroke.
- MORE--MOexipril and REgression of left ventricle hypertrophy in combination therapy A multicentric open label clinical trial.
- Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension.
- Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas.
- Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
- A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
- Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey.
- Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.
- (5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1.
- Insulin resistance in men with treated hypertension at increased risk for cardiovascular disease: results of a 3-year study.
- PPARgamma in endothelial cells influences high fat diet-induced hypertension.
- Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke.
- The British Cardiac Society Working Group definition of myocardial infarction: implications for practice.
- Catecholamines augment collateral vessel growth and angiogenesis in hindlimb ischemia.
- Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure.
- Pentoxifylline attenuates cardiac dysfunction and reduces TNF-alpha level in ischemic-reperfused heart.
- Lactadherin promotes VEGF-dependent neovascularization.
- PI 3-kinase p110beta: a new target for antithrombotic therapy.
- Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
- Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial.
- Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.
- Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors.
- Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor.
- Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists.
- Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
- The ATP-sensitive potassium channel blocker glibenclamide prevents renal ischemia/reperfusion injury in rats.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 Next >